NewsBenzinga리어, 2026회계연도 매출 가이던스 235억 4천만~240억 1천만 달러에서 233억 5천만~237억 5천만 달러로 하향 조정, 예상치 237억 9천 8백만 달러 리어, 2026회계연도 매출 가이던스 235억 4천만~240억 1천만 달러에서 233억 5천만~237억 5천만 달러로 하향 조정, 예상치 237억 9천 8백만 달러 Benzinga 2026.10.30 11:04 (GMT+0) Open on Benzinga Other news ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate Bithumb to Delist Fetch.ai (FET) on December 7 Sony Group Q2 EPS ¥76.48, Sales ¥3.429T
ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate
Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate
